Compare Amylx Pharmaceuticals Inc (AMLX) vs Starbucks Corp (SBUX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Starbucks Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Starbucks Corp trades at $106.09 (market cap $120.82B). The key difference: Starbucks Corp is far larger — about 61× Amylx Pharmaceuticals Inc's market cap, and Starbucks Corp pays a 2.34% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SBUX | |
|---|---|---|
Market Cap | $1.98B | $120.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $106.82 |
52-Week Low | $7.64 | $78.46 |
Enterprise Value | $1.70B | $143.51B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Starbucks (SBUX) trades at $106.01, down 0.38% today, with a bullish technical signal and recent earnings beat in Q1 2026. The company's revenue grew to $37.18B in 2025, though net income margin compressed to 3.89%. Recent news highlights AI initiatives to cut software costs, while analyst consensus is split evenly between Buy and Hold ratings with a $107.67 price target.
Outlook remains mixed: AI cost savings and loyalty growth offer upside, but margin pressure and high P/E of 80.92 pose risks. Near-term performance hinges on Q2 2026 earnings versus the $0.65 EPS estimate and execution of operational efficiencies amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
